Sunday, January 18, 2015 4:16:04 PM
Not to change the subject 
... your "Stable Disease" caught my attention and since I don't follow PPHM let me ask your opinion (or any one else who cares to comment) about something else that sometimes occurs in trials. When a company runs a trial with the comparator arm being "Physician's choice" what do you think of the trial? IF your answer is each indication stands on its own I am thinking of the NKTR-102 BEACON study in recurrent Breast Cancer. I didn't like the company not partnering and it is a concern that the wide variety of treatment options could led to better care in the physician's choice arm especially with new tools like what FMI offers.
... your "Stable Disease" caught my attention and since I don't follow PPHM let me ask your opinion (or any one else who cares to comment) about something else that sometimes occurs in trials. When a company runs a trial with the comparator arm being "Physician's choice" what do you think of the trial? IF your answer is each indication stands on its own I am thinking of the NKTR-102 BEACON study in recurrent Breast Cancer. I didn't like the company not partnering and it is a concern that the wide variety of treatment options could led to better care in the physician's choice arm especially with new tools like what FMI offers.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
